Thomas Nagy - Novozymes Executive VP of Supply Operations
NVZMY Stock | USD 54.46 0.40 0.73% |
EVP
Mr. Thomas Nagy was Executive Vice President of Supply Operations at Novozymes AS since April 1 2013. Before that he has served as Executive Vice President of Stakeholder Relations and COS at the Company since October 2007. He is also Member of the Board of Directors of the American Chamber of Commerce in Denmark EuropaBIO and Biobased Industries Joint Undertaking . At the Company he is responsible for Corporationrationrate Positioning Sustainability Development Corporationrationrate People and Organization and Facility Management. He joined the Company in 1986 as Chemical Engineer when Novozymes AS was the enzyme division of Novo Nordisk AS. Over the years he gained international experience in Brazil and the United States. Prior to his current position he was President of Novozymes North America Inc. from 2004 to 2007. He also held a number of technical and managerial positions within enzyme and insulin bulk production before being promoted to Vice President for Production Denmark and Global Procurement in 2000. He was also Member of the Executive Committee and Board of Directors of Biotechnology Industry Organization . He received his BS degree in Chemical Engineering from the Technical University in Copenhagen in 1985 and he is a graduate of Wharton School of Business AMP program in 2006. In addition he completed a number of business and management programs. since 2013.
Age | 50 |
Tenure | 11 years |
Phone | 45 44 46 00 00 |
Web | https://www.novozymes.com |
Novozymes Management Efficiency
The company has return on total asset (ROA) of 0.1062 % which means that it generated a profit of $0.1062 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2789 %, meaning that it generated $0.2789 on every $100 dollars invested by stockholders. Novozymes' management efficiency ratios could be used to measure how well Novozymes manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
Return On Equity | 0.28 | |||
Return On Asset | 0.11 |
Novozymes AS Leadership Team
Elected by the shareholders, the Novozymes' board of directors comprises two types of representatives: Novozymes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novozymes. The board's role is to monitor Novozymes' management team and ensure that shareholders' interests are well served. Novozymes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novozymes' outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Videbaek, COO and Executive VP of Bus. Devel. | ||
Tobias Bjorklund, Head of Investor Relations | ||
Ester Baiget, Pres CEO | ||
Kasim Kutay, Director | ||
Anders Lund, Executive Vice President Household Care & Technical Industries | ||
Agnete RaaschouNielsen, Director | ||
Thomas Nagy, Executive VP of Supply Operations | ||
Pedro Fernandes, Head America | ||
Joergen Rasmussen, Independent Director | ||
Andrew Fordyce, Executive VP of Food and Beverages | ||
Lena Halskov, Director, Employee Representative | ||
Tue Micheelsen, VP Marketing | ||
Sebastian Sderberg, VP Acquisitions | ||
Martin Riise, Head of Investor Relations | ||
Peder Nielsen, CEO and Pres | ||
Prisca HavranekKosicek, CFO & Executive Vice President Corporate Functions | ||
HeinzJuergen Bertram, Independent Director | ||
Benny Loft, CFO and Executive VP | ||
Anders Knudsen, Director, Employee Representative | ||
Lena Olving, Independent Director | ||
Mathias Uhlen, Independent Director | ||
Graziela Malucelli, Supply Operations | ||
Patricia Malarkey, Director | ||
Henrik Gurtler, Chairman of the Board | ||
Per Falholt, Consultant | ||
Kim Stratton, Director | ||
Tina Fanoe, Executive Vice President Agriculture & Bioenergy | ||
Morten Rasmussen, Sustainability People | ||
Thomas Bomhoff, Head of Investor Relations | ||
Lars Green, Director | ||
MSc MSc, Ex CFO | ||
Lars Koeppler, Independent Director, Employee Representative |
Novozymes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novozymes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.28 | |||
Return On Asset | 0.11 | |||
Profit Margin | 0.21 % | |||
Operating Margin | 0.26 % | |||
Current Valuation | 14.47 B | |||
Shares Outstanding | 276.6 M | |||
Price To Earning | 34.25 X | |||
Price To Book | 6.12 X | |||
Price To Sales | 0.80 X | |||
Revenue | 17.55 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novozymes AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Novozymes Pink Sheet analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |